Comparing Sintx Technologies (NASDAQ:SINT) and ResMed (NYSE:RMD)

Sintx Technologies (NASDAQ:SINT) and ResMed (NYSE:RMD) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Institutional & Insider Ownership

18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 4.1% of Sintx Technologies shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dividends

Sintx Technologies pays an annual dividend of $0.60 per share and has a dividend yield of 35.7%. ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.2%. Sintx Technologies pays out -12.2% of its earnings in the form of a dividend. ResMed pays out 25.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years. Sintx Technologies is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Sintx Technologies and ResMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-848.20%	-354.44%	-115.37%
ResMed	26.94%	25.58%	18.89%

Valuation and Earnings

This table compares Sintx Technologies and ResMed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.08 million	6.69	-$10.36 million	($4.91)	-0.34
ResMed	$5.65 billion	5.83	$1.52 billion	$10.43	21.93

ResMed has higher revenue and earnings than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Sintx Technologies and ResMed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1	0	3	0	2.50
ResMed	0	9	7	0	2.44

Sintx Technologies presently has a consensus target price of $9.33, suggesting a potential upside of 455.56%. ResMed has a consensus target price of $241.69, suggesting a potential upside of 5.69%. Given Sintx Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Sintx Technologies is more favorable than ResMed.

Summary

ResMed beats Sintx Technologies on 10 of the 16 factors compared between the two stocks.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

About ResMed

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN’s software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.